(Q37880216)

24 August 2017

1 reference

title

Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation (English)

1 reference

24 August 2017

Yoshitaka Sekido

1

1 reference

24 August 2017

2 May 2011

1 reference

24 August 2017

Pathology International

1 reference

24 August 2017

61

1 reference

24 August 2017

6

1 reference

24 August 2017

331-344

1 reference

Advances in malignant mesothelioma

24 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The pathogenesis of mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Problems in mesothelioma diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Cytogenetic and molecular genetic changes in malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

LATS2 is a tumor suppressor gene of malignant mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Neurofibromatosis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Functional inactivation of NF2/merlin in human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Organizing the cell cortex: the role of ERM proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Localization to the cortical cytoskeleton is necessary for Nf2/merlin-dependent epidermal growth factor receptor silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Fluorescence resonance energy transfer analysis of merlin conformational changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

p21-activated kinase links Rac/Cdc42 signaling to merlin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Cyclic AMP-dependent protein kinase phosphorylates merlin at serine 518 independently of p21-activated kinase and promotes merlin-ezrin heterodimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Tumorigenic transformation by CPI-17 through inhibition of a merlin phosphatase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin in organ size control and tumorigenesis: Hippo versus EGFR?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The role of the CD44/ezrin complex in cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

CD44, a therapeutic target for metastasising tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The increasing complexity of the cancer stem cell paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin, a "magic" linker between extracellular cues and intracellular signaling pathways that regulate cell motility, proliferation, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Rac1 GTPase: a "Rac" of all trades.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin/NF-2 mediates contact inhibition of growth by suppressing recruitment of Rac to the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin, the Product of the Nf2 Tumor Suppressor Gene, Is an Inhibitor of the p21-Activated Kinase, Pak1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Re-expression of the tumor suppressor NF2/merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Targeting the mTOR signaling network for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Combined treatment with cisplatin and sirolimus to enhance cell death in human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Inhibition of the met receptor in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Inhibition of Met/HGF receptor and angiogenesis by NK4 leads to suppression of tumor growth and migration in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

AXL regulates mesothelioma proliferation and invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Nf2/Merlin: a coordinator of receptor signalling and intercellular contact

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The Na+/H+ exchanger regulatory factor stabilizes epidermal growth factor receptors at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Contact-dependent inhibition of EGFR signaling by Nf2/Merlin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin and the ERM proteins--regulators of receptor distribution and signaling at the cell cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

NF2deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

NF2-deficient cells depend on the Rac1-canonical Wnt signaling pathway to promote the loss of contact inhibition of proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The NF2 tumor suppressor, Merlin, regulates epidermal development through the establishment of a junctional polarity complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

A mouse model recapitulating molecular features of human mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

A conditional mouse model for malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

From cell structure to transcription: Hippo forges a new path

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Hippo signaling in organ size control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The Hippo-YAP pathway: new connections between regulation of organ size and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The hippo signaling pathway in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Kibra functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Kibra is a regulator of the Salvador/Warts/Hippo signaling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

The WW domain protein Kibra acts upstream of Hippo in Drosophila.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Ajuba LIM proteins are negative regulators of the Hippo signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

A novel 4.1 ezrin radixin moesin (FERM)-containing protein, 'Willin'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Lats2 is an essential mitotic regulator required for the coordination of cell division.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Components of the Hippo pathway cooperate with Nek2 kinase to regulate centrosome disjunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Expression of Yes-associated protein in common solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Hippo signaling at a glance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

TEAD mediates YAP-dependent gene induction and growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1827.2011.02666.X

10.1111/J.1440-1827.2011.02666.X

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21615608